What has prevented the expansion of insulin sensitisers?

Bibliography

• SALTIEL AR, OLEFSKY JM: PPARγ and the treatment of insulin resistance. Trend Endocrinol. Metab. (2000) 11:362-368.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, DAY C: Thiazolidinediones today. Br. J. Diab. Vasc. Dis. (2001) 1:7-13.
   Google Scholar
• OWENS, DR: Thiazolidinediones: a pharmacological overview. Clinical Drug Investigation (2002) 22:485-505.
   Web of Science ®Google Scholar
• LEFF T, REED JE: The antidiabetic PPAR-γ ligands: an update on compounds in development. Curr. Med. Chem. – Immunol., Endoc. & Metab. Agents (2002) 2:33-47.
   Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR) J. Biol. Chem. (1995) 270:12953.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, COBB JE, COWAN DJ et al.: The structure–activity relationship between peroxisome proliferator-activated receptorγ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. (1996) 39:665-668.
   PubMed Web of Science ®Google Scholar
• BERGER J, BAILEY P, BISWAS C et al., Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology (1996) 137:4189-4195.
   Google Scholar
• SPIEGELMAN BM: PPARγ adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 47:507-514.
   Google Scholar
• SOHDA T, MEGURO K, KAWAMATSU Y: Studies on antidiabetic agents. IV. Synthesis and activity of the metabolites of 5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4-thiazolidinedione (ciglitazone). Chem. Pharm. Bull. (1984) 32:2267-2278.
   PubMed Web of Science ®Google Scholar
• CHANG AY, WYSE BM, GILCHRIST BJ, PETERSON T, DIANI AR: Ciglitizone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes (1983) 32:830-838.
   Google Scholar
• SOHDA T, MOMOSE Y, MEGURO K, KAWAMATSU Y, SUGIYAMA Y, IKEDA H: Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittel-Forschung (1990) 40:37-42.
   PubMed Web of Science ®Google Scholar
• SOHDA T, MIZUNO K, MOMOSE Y, IKEDA H, FUJITA T, MEGURO K: Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. J. Med. Chem. (1992) 35:2617-2626.
   PubMed Web of Science ®Google Scholar
• HOFMANN CA, COLCA JR: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care (1992) 15:1075-1078.
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, YOSHIOKA S, YOSHIOKA T, USHIYAMA I, HORIKOSHI H: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes (1988) 37:1549-1558.
   Google Scholar
• KLETZIEN RF, CLARKE SD, ULRICH RG: Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. (1992) 41:393.
   PubMed Web of Science ®Google Scholar
• KLETZIEN RF, FOELLMI LA, HARRIS P, WYSE BM, CLARKE SD: Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol. Pharmacol. (1992) 42:558.
   PubMed Web of Science ®Google Scholar
• HARRIS PK, KLETZIEN RF: Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol. Pharmacol. (1994) 45:439.
   PubMed Web of Science ®Google Scholar
• CHAWLA A, SCHWARZ EJ, DIMACULANGAN DD, LAZAR MA: Peroxisome proliferator-activated receptor (PPAR)γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology (1994) 135:798-800.
   Google Scholar
• SUZUKI A, YASUNO T, KOJO H, HIROSUMI J, MUTOH S, NOTSU Y: Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones. Jpn J. Pharmacol. (2000) 84:113-123.
   PubMedGoogle Scholar
• BOGACKA I, XIE X, BRAY GA, SMITH SR: The effect of pioglitazone on peroxisome proliferator-activated receptor- target genes related to lipid storage in vivo. Diabetes Care (2004) 27:1660-1667.
   Google Scholar
• BOGACKA I, XIE X, BRAY GA, SMITH S: Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes (2005) 54:1392-1399.
   Google Scholar
• WILSON-FRITCH L, BURKART A, BELL G et al.:Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol. Cell Biol. (2003) 23:1085-1094.
   PubMed Web of Science ®Google Scholar
• LACIVITA KA, VILLARREAL G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr. Med. Res. Opin. (2002) 18(6):363-370.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RB, KENDALL DM, DEEG MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care (2005) 28:1547-1554.
   Google Scholar
• LEHMANN JM, LENHARD JM, OLIVER BB, RINGOLD GM, KLIEWER SA: Peroxisome proliferator-activated receptors and are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. (1997) 272:3406-3410.
   PubMed Web of Science ®Google Scholar
• REGINATO MJ, BAILEY ST, KRAKOW SL et al.: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor-activating properties. J. Biol. Chem. (1998) 273:32679-32684.
   PubMed Web of Science ®Google Scholar
• MISRA P, CHAKRABAERTI RR, VIKRAMADITHYAN K et al.: PAT5A: a partial agonist of peroxisome proliferator-activated receptorγ is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J. Pharmacol. Exp. Ther. (2003) 306:763-771.
   PubMed Web of Science ®Google Scholar
• COLCA JR, BOLTEN CW, MAZZARELLA R et al.: Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPARγ. (In Preparation).
   Google Scholar
• SAVAGE DB, TAN GD, ACERINI CL et al.: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor. Diabetes (2003) 52:910-917.
   Google Scholar
• MEIRHAEGHE A, COTTEL D, AMOUYEL P, DALLONGEVILLE J: Association between peroxisome proliferator-activated receptor-γ haplotypes and the metabolic syndrome in french men and women. Diabetes (2005) 54:3043-3048.
   Google Scholar
• MILES PDG, BARAK Y, EVANS RM, OLEFSKY JM: Effect of heterozygous PPAR deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Am. J. Physiol. Endocrinol. Metab. (2003) 284:618.
   PubMedGoogle Scholar
• MATSUSUE K, HALUZIK M, LAMBERT G et al.: Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. (2003) 111:737-747.
   PubMed Web of Science ®Google Scholar
• HE W, BARAK Y, HEVEVER A et al.: Adipose specific peroxisome proliferators-activated receptorγ knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA (2003) 100:15712-15717.
   PubMed Web of Science ®Google Scholar
• BURANT CF, SREENAN S, HIRANO K et al.: Troglitazone action is independent of adipose tissue J. Clin. Invest. (1997) 100:2900-2908.
   PubMed Web of Science ®Google Scholar
• NORRIS AW, CHEN L, FISHER SJ et al.: Muscle-specific PPAR-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. (2003) 112:608-618.
   PubMed Web of Science ®Google Scholar
• CHAWLA A, BARAK Y, NAGY L, LIAO D, TONTONOZ P, EVANS RM: PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. (2001) 7:48-52.
   PubMed Web of Science ®Google Scholar
• CROSBY MB, SVENSON JL, ZHANG J, NICOL CJ, GONZALEZ FJ, GILKESON GS: Peroxisome proliferation-activated receptor (PPAR)γ is not necessary for synthetic PPARγ agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J. Pharm. Exper. Ther. (2005) 312:69-76.
   PubMed Web of Science ®Google Scholar
• PALAKURTHI SS, AKTAS H, GRUBISSICH L, MORTENSEN R, HALPERIN JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptorγand mediated by inhibition of translation initiation. Cancer Res. (2001) 61:6213-6218.
   PubMed Web of Science ®Google Scholar
• FEINSTEIN DL, SPAGNOLO A, AKAR C et al.: Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem. Pharmacol. (2005) 70:177-188.
   PubMed Web of Science ®Google Scholar
• DELLO RUSSO C, GAVRILYUK V, WEINBERG G et al.: Peroxisome proliferator-activated receptor thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. (2003) 278:5828-5836.
   PubMed Web of Science ®Google Scholar
• BRUNMAIR B, STANIEK K, GRAS F et al.: Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes (2004) 53:1052-1059.
   Google Scholar
• BRUNMAIR B, GRAS F, NESCHENS et al.: Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes (2001) 50:2309-2315.
   Google Scholar
• LEE MK, OLEFSKY JM: Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism (1995) 44:1166-1169.
   Google Scholar
• RITOV VB, MENSHIKOVA EV, HE J, FERRELL RE, GOODPASTER BH, KELLEY DE: Deficiency of subsarcolemmal mitochondria in obesity and Type 2 diabetes. Diabetes (2005) 54:8-14.
   Google Scholar
• YOUNG PW, BUCKLE DR, CANTELLO BC et al.: Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor. J. Pharmacol. Exp. Ther. (1998) 284:751-759.
   Google Scholar
• COLCA JR, McDONALD WG, WALDON DJ et al.: Identification of a novel mitochondrial protein (‘mitoNEET’) cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. (2004) 286:252-260.
   PubMed Web of Science ®Google Scholar
• REVUELTA MP: Cumulative insults to mitochondrial function may promote the emergence of syndrome X and diabetes mellitus in HIV/HCV co-infected patients. Mitochondrion (2004) 4:175-184.
   PubMed Web of Science ®Google Scholar
• SCHWATZ F, DUKA A, SUN F, CUI J, MANOLIS A, GAVRAS H: Mitochondrial genome mutations in hypertensive individuals. Am. J. Hypertens. (2004) 17:629-635.
   PubMed Web of Science ®Google Scholar
• WILSON FW, HARIRI A, FARHI A et al.: A cluster of metabolic defects caused by a mutation in mitochondrial tRNA. Science (2004) 306:1190-1194.
   Google Scholar
• WISLØFF U, NAIJAR SM, ELLINGSEN Ø et al.: Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science (2005) 307:418-420.
   Google Scholar
• COLCA JR: Insulin sensitizers may prevent metabolic inflammation. Biochem. Pharmacol. (2006) 71: (In Press).
   Google Scholar
• RUDERMAN NB, SAHA AK, VAVVAS D, WITTERS LA: Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. (1999) 276:1-18.
   PubMed Web of Science ®Google Scholar
• PUIGSERVER P, SPIEGELMAN BM: Peroxisome proliferator-activated receptor-coactivator 1 (PGC-1): transcriptional coactivator and metabolic regulator. Endocr. Rev. (2003) 24:78-90.
   PubMed Web of Science ®Google Scholar
• ZHANG H, ZHANG A, KOHAN DE, NELSON RD, GONZALEZ FJ, YANG T: Collecting duct-specific deletion of peroxisome proliferator-activated receptorγ blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. USA (2005) 102:9406-9411.
   PubMed Web of Science ®Google Scholar
• GUAN Y, HAO C, CHA DR et al.: Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat. Med. (2005) 11:861-866.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, WOLSKI K, TOPOL EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. J. Am. Med. Assoc. (2005) 294:2581-2586.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet (2005) 366(9493):1279-1289.
   PubMed Web of Science ®Google Scholar
• LOWELL BB: PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell (1999) 99:230-253.
   Google Scholar
• BOLTEN CW, PAYNE M, HERON M, COLCA JR: Anti-hypertensive pharmacology of thiazolidinediones in the Dahl-Salt-Sensitive model. (In Preparation).
   Google Scholar
• HARRIGAN GG, COLCA JR, SZALMAS, BOROS LG: PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: a comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells. Metabolomics (2006) 1: (In Press).
   Google Scholar
• KIM J-H, LEWIN TM, COLEMAN RA: Expression and characterization of recombinant rat acyl-CoA synthases 1,5 and 5. Selective inhibition by triacsin C and thiazolidinediones. J. Biol. Chem. (2001) 276:24667-24673.
   PubMed Web of Science ®Google Scholar